drugset / Trial / NCT00681863
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria and who have completed either Study 248.641 (NCT 00681863) or 248.644 (NCT 00558467).
Timeline
- Start
- 2008-05
- Primary completion
- 2009-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 0.0625 mg | — |
| Comparator | Pramipexole | Unknown | 0.125 mg | — |
| Comparator | Pramipexole | Unknown | 0.25 mg | — |